A curated collection of human vaccination response signatures

Authors

Kenneth C. Smith^{1*}, Daniel G. Chawla^{2*}, Bhavjinder K. Dhillon^{3*}, Zhou Ji¹, Randi Vita⁴, Eva van der Leest³, Jessica Weng³, Ernest Tang³, Amani Abid³, The Human Immunology Project Consortium (HIPC)[&], Bjoern Peters^{4,6}, Robert E.W. Hancock^{3,**}, Aris Floratos^{1,7,**}, Steven H. Kleinstein^{2,5,8,**}

*co-first authors

**co-senior authors

Affiliations

¹Department of Systems Biology, Columbia University, New York, New York, USA

²Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA

³Department of Microbiology & Immunology, University of British Columbia, Vancouver, Canada

⁴Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA

⁵Department of Pathology, Yale School of Medicine, New Haven, CT, USA

⁶Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA

⁷Department of Biomedical Informatics, Columbia University, New York, New York, USA

⁸Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA

& Members of the HIPC Steering Committee: Raphael Gottardo (Fred Hutchinson Cancer Research Center, Seattle, WA, USA); Elias K. Haddad (Drexel University, Philadelphia, PA, USA); David A. Hafler (Yale School of Medicine, New Haven, CT, USA); Eva Harris (University of California, Berkeley, Berkeley, CA, USA); Donna Farber (Columbia University Medical Center, New York, NY, USA); Steven H. Kleinstein (Yale School of Medicine, New Haven, CT, USA); Ofer Levy (Boston Children's Hospital, Boston, MA, USA); Julie McElrath (Fred Hutchinson Cancer Research Center, Seattle, WA, USA); Ruth R. Montgomery (Yale School of Medicine, New Haven, CT, USA); Bjoern Peters (La Jolla Institute for Immunology, La Jolla, CA, USA); Bali Pulendran (Stanford University School of Medicine, Stanford University, Stanford, CA, USA); Adeeb Rahman (Icahn School of Medicine at Mount Sinai, New York, New York, USA); Elaine F. Reed (David Geffen School of Medicine at University of California, Los Angeles, CA, USA); Nadine Roupheal (Emory University School of Medicine Decatur, Atlanta, GA, USA); Minnie Sarwal (University of California, San Francisco, San Francisco, CA, USA); Rafick Sekaly (Emory University School of Medicine Decatur, Atlanta, GA, USA); Ana Fernandez-Sesma (Icahn School of Medicine at Mount Sinai, New York, New York, USA); Alessandro Sette (La Jolla Institute for Immunology, La Jolla, CA, USA); Ken Stuart (Seattle Children's Research Institute, Seattle, WA, USA); John S Tsang (NIAID and Center for Human Immunology (CHI), NIH, Bethesda, MD, USA)

corresponding authors: Aris Floratos (af2202@cumc.columbia.edu), Steven Kleinstein (steven.kleinstein@yale.edu)

Abstract

Recent advances in high-throughput experiments and systems biology approaches have resulted in hundreds of publications identifying “immune signatures”. Unfortunately, these are often described within text, figures, or tables in a format not amenable to computational processing, thus severely hampering our ability to fully

exploit this information. Here we present a data model to represent immune signatures, along with the Human Immunology Project Consortium (HIPC) Dashboard (www.hipc-dashboard.org), a web-enabled application to facilitate signature access and querying. The data model captures the biological response components (e.g., genes, proteins or cell types or metabolites) and metadata describing the context under which the signature was identified using standardized terms from established resources (e.g., HGNC, Protein Ontology, Cell Ontology). We have manually curated a collection of >600 immune signatures from >60 published studies profiling human vaccination responses for the current release. The system will aid in building a broader understanding of the human immune response to stimuli by enabling researchers to easily access and interrogate published immune signatures.

Introduction

Systems-level profiling of the human immune system has generated important insights into the mechanisms by which humans respond to exposures such as vaccination. These studies, including many conducted through the Human Immune Project Consortium (HIPC), have generated hundreds of publications. While repositories exist to promote re-use of primary experimental immunology data generated from these efforts, such as the Gene Expression Omnibus¹ (GEO) and the NIAID Division of Allergy, Immunology, and Transplantation (DAIT)-sponsored Immunology Database and Analysis Portal² (ImmPort), there is no centralized framework to aggregate and organize the published findings resulting from the analysis of this data, and particularly the coherent sets of biomarkers, termed here “signatures”. Additionally, such signatures are not published in a consistent format between publications and may be presented as text, tables, or images. This heterogeneity presents a barrier to comparative analyses since identifying published signatures, for example of a vaccine response, requires extensive manual curation of the literature that must be repeated by investigators each time they wish to interpret a set of results. Here, we propose a model to standardize the representation of these published findings and present the Human Immunology Project Consortium (HIPC) Dashboard—a searchable interface to query curated signatures from the corpus of human immunology literature.

We define a ‘signature’ as the information required to specify a published result. This includes alterations in the levels of a set of one or more response component(s), i.e., biological entities such as genes or cell types, that are defined by a particular comparison in the context of an immune exposure. The signature also includes contextual information (termed metadata) such as the conditions and circumstances under which the signature was identified, the tissues or cells that were assayed, as well as clinical data such as demographic information about the groups that were included in the analysis. As a motivating example, a study by Bucasas et al.³ identified a set of genes that are up-regulated in individuals with higher antibody responses (comparison) after vaccination with the 2008-2009 trivalent influenza vaccine (exposure) in an adult cohort. The expression of genes STAT1, IRF9, SPI1, CD74, HLA-E, and TNFSF13B one day after influenza vaccination was predictive of greater antibody responses. In the paper, these results were represented in a table, though similar findings often appear as text or within figures. Without standardization, such findings are not easily accessible to the wider scientific community for further analysis.

Several existing resources define pathway or gene module signatures through re-analysis of raw data, but none capture the original findings published with these data. Among these resources are the OMics Compendia Commons (OMiCC)⁴, the Molecular Signatures Database (MSigDB)^{5,6}, and EnrichR^{7,8}. OMiCC crowdsources annotations for gene expression data to be used in re-analysis and novel signature

generation. MSigDB and EnrichR offer biological annotations built from data re-analyzed en masse, but similarly do not necessarily capture published findings. While these tools are useful for contextualizing new gene expression findings in terms of pathways and enrichment scores, they are limited to gene expression results and do not offer direct comparisons against the high-value, expert-generated signatures available in the literature.

To improve access and to promote reuse of published signatures, we designed a data model that standardizes the content and context of published immune signatures. Our initial curation efforts have focused on gene expression and cell-type frequency/activation signatures of human vaccine responses, but this framework is extensible to other domains such as response to infection. We captured what is changing, (e.g. groups of genes), how that response component changed (e.g. up- or down-regulation), where this change was observed (e.g. in sorted CD8+ T cells from adults), and the comparison that was performed (e.g. individuals with high vs. low antibody titers post-vaccination). We then manually curated signatures from publications both within and outside of HIPC that described changes in gene expression, cell-type frequencies or cell activation state in response to vaccination. To disseminate these immune signatures, we developed the HIPC Dashboard (www.hipc-dashboard.org), a web-accessible, user-friendly interface to enable signature searching and browsing, and to facilitate rapid comparative analyses. The design of the HIPC Dashboard is based on a similar infrastructure we developed previously for the Cancer Target Discovery and Development network, the CTD² Dashboard⁹, and leverages the same underlying ontological framework for the standardized representation of research findings as well as the emphasis on the consistent, curation-mediated use of controlled vocabularies for linking findings reported in different publications.

Results

A Data Model for Immune Signatures

We developed a data model that captures, in a detailed and consistent format, the essential information embedded in published immune signatures (**Table 1**). Key elements of this data model (e.g., genes, vaccines, etc.) are specified using controlled vocabularies, thus making immune signatures amenable to data mining. A signature as defined in this model encapsulates both a change in the behavior or abundance of a biological response component as well as the metadata describing the context under which the signature is identified, including (1) the tissue in which the signature was observed, (2) the immune exposure and timing underlying the observed comparison, and (3) clinical details of the cohort from which tissue samples were taken, such as sex and age (**Figure 1**). The model accommodates many types of biological response components (gene, protein, metabolite, pathway, and cell type (e.g. subsets of blood cells).

To facilitate data mining and comparative analyses between different conditions including vaccine types, and to afford consistency between this database and other projects using the same controlled vocabulary terms, standardized terms and ontology links were used for as many biological response components, immune exposures, and demographic fields as possible. Gene and cell type response components were standardized to the HGNC¹⁰ (as provided through the NCBI) and Cell Ontology^{11,12} (CL) respectively to enable comparisons across publications using different naming conventions. Cell types from the Cell Ontology were further differentiated using protein marker terms drawn from Protein Ontology¹³ (PRO), where possible (e.g. CD4+ T cells). This same naming convention is used to describe the tissue in which the signature was observed¹⁴.

166
167 To annotate the immune challenges driving each signature, we utilized the Immune
168 Exposure model¹⁵, which provides a standardized description of a broad range of
169 potential and actual exposures to different immunological agents (e.g., from
170 laboratory confirmed infection to living in an endemic area). Immune exposures are
171 broken down into Exposure Process, Exposure Material, Disease Name, and Disease
172 Stage. Each of these components is modeled using standardized ontology
173 terminology. For example, Exposure Materials such as vaccines are captured using
174 terms in the Vaccine Ontology¹⁶ (VO), which further link to target pathogens and
175 strains using the NCBI Taxonomy^{17,18}. Utilization of the Immune Exposure model
176 promotes interoperability with other projects that have adopted its use, both within
177 and outside of HIPC, including data repositories such as ImmPort and the Immune
178 Epitope Database¹⁹.

179
180 Cohort information that is important for interpreting signatures is also captured, such
181 as age range and cohort type (e.g., “healthy adults”). An additional subgroup field
182 specifies if a given signature only applies to a subset of individuals, for example the
183 female subjects or those with a high antibody response within a larger cohort²⁰.
184 Additional fields describe the particular perturbations that drive the changes to the
185 biological response components. The “comparison” field describes the cohort groups
186 whose differential response under the perturbation is measured. Examples of
187 comparison groups include measurements taken at two different time points (e.g.
188 day1 vs. day 0), correlation with antibody response, differing antibody response
189 outcomes (e.g. high vs. low responders), or comparisons across different
190 demographic parameters such as age or sex (e.g. younger vs. older, female vs.
191 male). The “response_behavior” field captures the directionality of the differential
192 response (e.g. up- or down-regulated, positively- or negatively-correlated) under the
193 specified comparison. Fields for which a formal controlled vocabulary was not used,
194 such as cohort descriptions and the comparison, are stored as free text.

195
196 Finally, each signature is tagged with a Pubmed ID (PMID) and publication year field,
197 to connect observations to their literature sources.

198 199 *Manual Curation of Published Signatures*

200
201 A defined Pubmed search strategy was used (see Methods) to assemble an initial list
202 of publications comprising studies that involved a systems-level profiling of
203 measurable changes before and after vaccination in human subjects. The
204 publications were culled for signatures reporting statistically significant changes in
205 gene expression, cell-type frequency or cell activation state induced by an immune
206 exposure when comparing groups with different features (such as high vs low
207 responders as defined by antibody titers). We focused on components that also
208 included information about response behavior (e.g. up- or down-regulated). In total,
209 665 immune signatures were manually curated from 69 published studies. After
210 standardization and quality control (see Methods), these curated gene and cell type
211 signatures included 13,821 unique genes, 152 unique cell types (including protein
212 markers and additional type-modifiers), and 44 pathogens across 56 vaccines (**Table**
213 **2**). Table 3 illustrates a typical gene-expression type signature after tissue, gene
214 symbol and pathogen standardization.

215 216 *The HIPC Signatures Dashboard*

217 The data model provides a means for representing immune signatures in a
218 structured, standardized, machine-readable manner while the curation process
219 enables the cross-referencing of signatures from different publications on the basis of

their shared response components, by enforcing the consistent use of controlled vocabularies for codifying these components (e.g., genes, cell types, tissues, vaccines, and pathogen strains). These capabilities come together in the “HIPC Dashboard” (<http://hipc-dashboard.org>), a web application developed to enable dissemination of the curated set of immune response signatures. The HIPC Dashboard allows signature browsing, as well as searching for one or multiple response components (using the corresponding controlled vocabulary terms and their synonyms), to retrieve all immune signatures involving the query response component(s) across all curated publications.

The central viewable element of the HIPC Dashboard is the “Observation Summary”, a human-readable description of the information captured in an immune signature. Observation summaries are constructed “on the fly”, using template text devised as part of the curation process. The template has placeholders for the various elements of an immune signature, including the response component (gene or cell type) and the response behavior type (up/down or correlation). When a specific signature is selected in the process of browsing or searching the Dashboard, the observation summary for that signature is instantiated by replacing the template placeholders with the relevant values from that signature. For example, a joint search on the terms “CD4” and “Zostavax” yields about 35 observation summaries. One of these is related to a change in cell-type frequency:

In [peripheral blood mononuclear cell](#), [CD4-positive, alpha-beta memory T cell & CD38+](#), [HLA-DR+](#), [VZV tetramer+](#) frequency was **up** in cohort **seniors(50-75)** for the comparison **14d vs 0d** after exposure to [Zostavax](#) targeting [Human alphaherpesvirus 3](#) ([details_»](#))

In a second example, a joint search on the terms “CXCL10” and “BCG” yields 6 observation summaries, one of which reports a correlation of gene expression (at 1 day post-vaccination) to an ELISpot result at 28 days post-vaccination:

In [blood](#), [CXCL10](#) gene expression was **positively correlated** with **IFN-gamma ELISpot spot forming cell 28d** in subgroup **BCG-primed** of cohort **infants (4-6m)** after exposure to [MVA85A](#) targeting [Mycobacterium tuberculosis variant bovis BCG](#) ([details_»](#))

In both cases, placeholders in the observation summary template have been replaced by controlled terms for the response components and ontology-linked metadata (blue, hyperlinked text) and by free-text metadata describing informative experiment details (black, bold text). Following the hyperlink for a controlled term leads to a dedicated page for the corresponding biological entity, providing additional details (including links to relevant external annotation sources, e.g., Entrez, GeneCards and UniProt for genes) as well as a listing of all the immune signatures stored in the Dashboard that involve that entity (**Figure 2A**). Further, the “details” link at the end of each observation summary points to an “Observation” page (**Figure 2B**) containing detailed information about the corresponding immune signature, including a full listing of all its available metadata. This includes, for example, structured text for values such as age group and days post-immunization, and links to download the full signature source data (including all metadata) in tab-delimited form. Additionally, each observation includes a link to a file containing the complete set of response components from which it was derived, e.g. the full list of genes or cell types.

Discussion

Users of the HIPC Dashboard can easily search and examine hundreds of immune signatures related to human vaccination responses. Consolidating these publications, standardizing their findings in a database, and disseminating them through the Dashboard interface allows for rapid comparative analyses and re-use of published findings. This is particularly important for identifying commonalities across studies that may reflect shared mechanisms. The HIPC Dashboard can offer broad insights into the mechanisms by which our immune systems respond to vaccination and will be of great value to the vaccine research community.

As of the date of this publication, 152 unique cell types and 13,821 distinct genes have been collected in the HIPC Dashboard; this large number of published results allows users to quickly examine the role of particular biological response components, such as individual genes or cell types, across studies. Most of the currently curated gene signatures have fewer than 50 genes, with a range of 1 to 2,038 (**Figure 3A**), while most cell-type frequency or cell activation state signatures have only a single cell type, with a range up to 9 (**Figure 3B**). These signatures represent findings from 16 tissues and tissue extracts, including blood, PBMCs, T cells, B cells, monocytes, and NK cells. Nearly 250 entries describe changes over time, more than 75 capture antibody response-associated signatures, and several others come from studies that report effects of age and T cell responses.

The frequency with which cell types and genes are reported in the Dashboard offers insights about key players of the human immune response to vaccination. The most common cell types across pathogens and comparisons are NK cells, CD4+ T cells, and CD8+ T cells. (**Figure 3C**). The most commonly reported genes are STAT1, a signalling protein stimulated by cytokines and interferons; GBP1, an interferon induced gene involved with innate immunity; IFI44L, a paralog of Interferon Stimulated Protein 44, and SERPING1, a complement cascade protein (**Figure 3D**). We searched the HIPC Dashboard for genes with vaccination signatures across six or more pathogens and found a set of 36 associated genes across 12 target pathogens (**Figure 3E**). Many are interferon stimulated genes, Toll-like receptors, or members of the complement cascade, potentially reflecting a common transcriptional program in response to many different vaccinations.

By design, our current implementation captures vaccination signatures as they are reported in the literature, but it does not include related methodological or statistical information regarding signature discovery (e.g. p-value cut-off) or provide analytical tools that can be applied to the curated signatures. Test statistics are not usually comparable across study designs, and we believe this information may give users a false sense that some signatures are more statistically reliable than others. We instead defer to the judgement of each study's authors and their peer reviewers, and capture signatures as they were reported in each publication. We also caution that bias regarding the number of times particular genes or cell types were investigated might skew relationships in the Dashboard, thus precluding certain types of analyses. As a result, high level analytical tools have not been integrated into the Dashboard, although all of the signatures with full metadata can be downloaded to enable the use of third-party tools. Despite this, we believe the signatures available in the HIPC Dashboard will allow the research community to quickly query the literature and provide valuable comparisons and context for their own experimental results.

The number of genes and cell types captured reflect publications curated through January 2021, but we anticipate the HIPC Dashboard will undergo regular updates to accommodate new findings and additional domains of interest. The current

implementation includes gene and cell type response components, as these represent the most commonly published signature types, but it will be valuable to also curate other response components, such as pathways, proteins, and metabolites. Additionally, we recognize that researchers may wish to compare a vaccine response against a particular pathogen to its corresponding disease response; it is easy to see how future iterations could expand the existing vaccine signature framework to capture signatures of infection. Based on our experience, we expanded the data model to include figure numbers or supplementary file annotations within publications as this can greatly simplify quality control during manual curation. We have provided links in the Dashboard to original sources wherever possible.

In summary, we present the HIPC Dashboard (hipc-dashboard.org) to provide the vaccine research community with easy access to hundreds of published human systems vaccinology signatures. This resource will allow researchers to rapidly compare their own experimental results against existing findings that may otherwise be difficult to locate in the literature. This resource encourages the re-use of published results for advancing our understanding of human vaccine responses and provides a framework that can be extended to capture signatures from other types of immune exposures.

Methods

Manual Curation

The initial list of publications to curate into the HIPC Dashboard were derived from a PubMed search of papers matching the terms “Vaccine [AND] Signatures” or “Vaccine [AND] Gene expression”. Two data curators manually collected a standard set of information from each study according to the designed data model (see **Figure 1**) and recorded it into a spreadsheet. Each signature was entered by one curator, and subsequently double-checked by the second curator. Table 3 shows a representative portion of the standardized information captured for each signature (12 data fields out of a total of 26).

Assays in the curated publications included gene expression analysis and measured changes in cell-type frequency and cell activation state. Each publication could give rise to any number and type of individual signatures. The signature content is centered on a list of biological response components (genes or cell types) that had a statistically significant change in the assay. These were designated as “response components” to capture different types of entities in a single standardized template column. For example, for gene expression assays, this was often a list of differentially expressed genes.

For genes, an initial manual curation process was applied to make a first pass at symbol standardization and detect any mistakes in copying. Gene names, symbols and or IDs (which may include HGNC symbols, Entrez IDs, Ensembl IDs etc.) were searched in turn against Panther, (www.pantherdb.org)²¹, using the “Functional classification viewed in gene list” search, followed if needed by searches against UniProt (www.uniprot.org)²² and NCBI (www.ncbi.nlm.nih.gov/search) until either a match or updated symbol was found; in the case of no match, the original representation was left unchanged. Any IDs that matched entries that were deprecated or defined as pseudogenes were removed from the curation.

Data Standardization

379 The manually curated data required further steps to match terms encountered to their
380 appropriate ontology representations. A number of the translations described below
381 were orchestrated using an R script, which generated files ready for loading into the
382 HIPC Dashboard.

383
384 *Gene symbols* - Outdated gene symbols and known aliases were translated to their
385 current NCBI representation, which is the HGNC symbol in all but one case. The first
386 pass of conversion used the function `alias2SymbolUsingNCBI()` from the
387 Bioconductor `limma` package with the most recent available gene annotation file.
388 This function returns either an exactly matching official symbol, or if none, the alias
389 with the lowest EntrezID. We followed this by a second R package, `HGNChelper`,
390 which was able to resolve additional unmatched gene symbols to valid NCBI
391 symbols. Genbank accession numbers were converted to gene symbols where
392 possible using the `org.Hs.egACCN2EG` translation table which is part of the
393 Bioconductor `org.Hs.eg.db` package²³. Selected symbols still not matching NCBI
394 names were investigated and corrected manually where possible after checking the
395 original publications for context or for errors in transcription. Symbols for which no
396 valid NCBI gene symbol was found, e.g. some pseudogenes, antisense, or
397 uncharacterized genes, are not included in the HIPC Dashboard proper, since a
398 requirement of the Dashboard framework is that all gene symbols must appear in the
399 controlled vocabulary (NCBI/HGNC). However, these symbols are included in
400 downloadable gene lists for each signature.

401
402 *Cell types* - Cell types as response components were first curated from the
403 publications as published using a combination of cell type terms and additional
404 descriptive terms, such as protein marker expression. This information was then
405 mapped to a combination of Cell Ontology and Protein Ontology terms, according to
406 a published model¹⁴. Note that cell types can appear in two different contexts, either
407 as response components themselves, or as the cell type isolated for gene expression
408 experiments. In some cases, additional information was provided which could not be
409 mapped to an ontology term¹⁴. This type of information related to a wide variety of cell
410 identification techniques and included the use of additional stains such as viability
411 dyes or tetramer staining. For each set of terms, an entry was created in a lookup
412 table by assigning (1) a parent cell type from the cell ontology, (2) mapping additional
413 protein marker terms to the protein ontology, and then (3) separately retaining as
414 free text descriptors not mapped to an ontology entry, such as tetramer specificity.
415 Thus the original entry was mapped to up to three descriptor columns, which can be
416 combined as needed for display purposes. For a full, translated cell type, the
417 displayed format is the cell ontology name followed by, if there are additional terms,
418 the "&" symbol, followed by any PRO terms and then any free text.

419
420 *Vaccines* - Vaccine names collected from the literature were manually mapped to the
421 most specific vaccine ontology term available. If a specific vaccine could not be found
422 in VO new terms were requested; some examples of terms we included were
423 VO_0004899 (2012-2013 seasonal trivalent inactivated influenza vaccine),
424 VO_0003961 (ChAd63-KH vaccine, *Leishmania donovani*), VO_0004890 (gH1-Qbeta
425 vaccine, novel pandemic-influenza), and VO_0004891 (CN54gp140+GLA, HIV-1).

426
427 *Pathogens* - The viral, bacterial or protozoan pathogens targeted by each vaccine are
428 represented with terms from the NCBI Taxonomy. For the case of influenza
429 vaccines, a table was created mapping vaccines by year of administration and type
430 (e.g. trivalent or quadrivalent) to their seasonal viral components, unless otherwise
431 indicated in the publication, e.g. for monovalent or specialized vaccines such as

432 *Pandemrix*. For the few cases where the exact viral strain was not present in the
433 NCBI Taxonomy, the closest more general term in the hierarchy was used. This
434 mapping table was used to substitute in the actual viral pathogen names.
435

436 **Data Availability**

437 Curated signatures are available on the HIPC Dashboard website ([http://hipc-](http://hipc-dashboard.org)
438 [dashboard.org](http://hipc-dashboard.org)) and Github (see Code Availability for details). Files listing all
439 response components for a signature can be downloaded from within individual
440 observations in the Dashboard. The complete set of signature data can be
441 downloaded from the GitHub repository at [https://github.com/floratos-lab/hipc-](https://github.com/floratos-lab/hipc-dashboard-pipeline)
442 [dashboard-pipeline](https://github.com/floratos-lab/hipc-dashboard-pipeline). This repository contains copies of the curated data rewritten after
443 all update and transformation steps, in the original spreadsheet format, as well as in
444 Broad GMT format.

445 **Code Availability**

446 Source curated data and mapping files (cell types, vaccine components, the NCBI
447 gene file used, etc.), as well as the R code for the processing pipeline used to create
448 the Dashboard submission files, are available on GitHub at
449 <https://github.com/floratos-lab/hipc-dashboard-pipeline>. The data in this paper
450 corresponds to pipeline and data version 1.0.1 in the pipeline GitHub repository.
451 Code for the HIPC Dashboard web interface is available on GitHub at
452 <https://github.com/floratos-lab/hipc-signature>.

453 *Supported web browsers* - The HIPC Dashboard has been tested on recent versions
454 of

- 455 • Chrome (Version 86.0.4240.183 (Official Build) (64-bit))
- 456 • Firefox (Version 82.0.2 (64-bit))
- 457 • Edge (Version 86.0.622.61 (Official build) (64-bit))

458 **Acknowledgements**

459 This research was performed as a project of the Human Immunology Project
460 Consortium (HIPC) and supported by the National Institute of Allergy and Infectious
461 Diseases. This work was supported in part by NIH grants U19AI128949,
462 U19AI118608, U19AI118626, and U19AI089992. This work was supported in part by
463 the Canadian Institutes of Health Research [funding reference number FDN-154287]
464

465 **Author contributions**

466 Conceptualization: AF, SHK; Methodology: KCS, DC, BKD, ZJ, RV, BP, REWH, AF,
467 SHK; Software: KCS, ZJ, AF; Investigation: KCS, DC, BKD, EvdL, JW, ET, AA;
468 Writing - Original Draft: KCS, DC, BKD, AF, SHK; Writing - Review and Editing: all
469 authors
470

471 **Competing interests**

472 S.H.K. receives consulting fees from Northrop Grumman
473

474 **Figure Legends**

475 **Figure 1.** Overview of the manual curation process for extracting immune signatures

from relevant publications into the HIPC signatures database and a web-accessible HIPC Dashboard. The middle panel highlights the various fields that are captured for a given immune signature, with examples provided in red font. Key fields are standardized using existing ontologies or pre-defined criteria in order to capture a wide array of signatures.

Figure 2. HIPC Dashboard web interface. **A.** Subject page for cell type “CD4-positive, alpha-beta T cell” showing a link-out to the Cell Ontology, the filtering box to further narrow the displayed observations, and the first two observation summaries (“Related observations”). **B.** Partial view of a details page for a CD4-positive, alpha-beta T cell observation. For each controlled term, its name, plus its class, role, and description are shown. Linked pages list details from the relevant ontology and list all observations containing that term. The class equates to its controlled vocabulary type; values are cell subset, gene, pathogen, and vaccine. Roles are used to further differentiate how each term, whether controlled or standardized, is being used. Among the classes in the HIPC Dashboard, only the class “cell subset” has more than one role, these being “tissue” and “cell_biomarker”. Full metadata, not shown here, is contained in the table labeled “Evidence” at the bottom.

Figure 3. Summarization of HIPC Dashboard contents. Signature size distributions showing the number of response components across **A.** gene and **B.** cell type signatures. **C.** Word cloud of the top 50 most frequent gene symbols and **D.** top 10 most frequent cell types, where size corresponds to the total number of observations in the Dashboard. **E.** Heatmap of recurring genes across vaccines targeting different pathogens. Temporally associated genes in adult whole blood or PBMCs were filtered to those with signatures for six or more pathogens. Color indicates up (red) or down (blue) regulation. Genes with opposing directions in multiple studies were marked ‘trends up’ or ‘trends down’ according to the most common direction (or marked ‘no consensus’ for perfect ties).

Tables

Table 1. Data model for capturing immune signatures. Genes and cell types are captured as response components, with terms standardized against NCBI/HGNC or CL+PRO, respectively. Exposures are captured and standardized against VO terms and NCBI Taxonomy IDs. Metadata includes observed tissue, study timing, and cohort age characteristics. *fields in the Immune Exposure model¹⁵

Table 2. Dashboard summary statistics for gene and cell-type signatures. “Joint” refers to the union of the two signature types, as they overlap in the various components. “Total Response Components” lists the number of genes or parent cell types from the Cell Ontology (CL) across all signatures. When additional cell-type markers are included, e.g. from the Protein Ontology (PRO), there are 152 unique cell types represented among the signatures. “Response Components per Signature” shows the range of the number of response components found in individual signatures.

Table 3. Key fields in the immune signature data model for a gene expression signature. This signature reports positive correlation between gene expression and a computed titer response index (TRI).

528 **References**

- 529 1. Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene
530 expression and hybridization array data repository. *Nucleic Acids Res.* **30**, 207–
531 210 (2002).
- 532 2. Bhattacharya, S. *et al.* ImmPort, toward repurposing of open access
533 immunological assay data for translational and clinical research. *Sci. Data* **5**,
534 180015 (2018).
- 535 3. Bucasas, K. L. *et al.* Early patterns of gene expression correlate with the humoral
536 immune response to influenza vaccination in humans. *J. Infect. Dis.* **203**, 921–
537 929 (2011).
- 538 4. Shah, N. *et al.* A crowdsourcing approach for reusing and meta-analyzing gene
539 expression data. *Nat. Biotechnol.* **34**, 803–806 (2016).
- 540 5. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene
541 set collection. *Cell Syst.* **1**, 417–425 (2015).
- 542 6. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based
543 approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci.*
544 **102**, 15545–15550 (2005).
- 545 7. Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list
546 enrichment analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
- 547 8. Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis
548 web server 2016 update. *Nucleic Acids Res.* **44**, W90-97 (2016).
- 549 9. Aksoy, B. A. *et al.* CTD2 Dashboard: a searchable web interface to connect
550 validated results from the Cancer Target Discovery and Development Network.
551 *Database J. Biol. Databases Curation* **2017**, (2017).
- 552 10. Yates, B. *et al.* Genenames.org: the HGNC and VGNC resources in 2017.
553 *Nucleic Acids Res.* **45**, D619–D625 (2017).
- 554 11. Bard, J., Rhee, S. Y. & Ashburner, M. An ontology for cell types. *Genome Biol.* **6**,

555 R21 (2005).

556 12. Diehl, A. D. *et al.* The Cell Ontology 2016: enhanced content, modularization, and
557 ontology interoperability. *J. Biomed. Semant.* **7**, 44 (2016).

558 13. Natale, D. A. *et al.* Protein Ontology (PRO): enhancing and scaling up the
559 representation of protein entities. *Nucleic Acids Res.* **45**, D339–D346 (2017).

560 14. Overton, J. A. *et al.* Reporting and connecting cell type names and gating
561 definitions through ontologies. *BMC Bioinformatics* **20**, 182 (2019).

562 15. Vita, R. *et al.* A structured model for immune exposures. *Database* **2020**, (2020).

563 16. He, Y. *et al.* VO: Vaccine Ontology. *Nat. Preced.* 1–1 (2009)
564 doi:10.1038/npre.2009.3552.1.

565 17. Sayers, E. W. *et al.* GenBank. *Nucleic Acids Res.* **47**, D94–D99 (2019).

566 18. Schoch, C. L. *et al.* NCBI Taxonomy: a comprehensive update on curation,
567 resources and tools. *Database J. Biol. Databases Curation* **2020**, (2020).

568 19. Vita, R. *et al.* The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids*
569 *Res.* **47**, D339–D343 (2019).

570 20. Voigt, E. A. *et al.* Sex Differences in Older Adults' Immune Responses to
571 Seasonal Influenza Vaccination. *Front. Immunol.* **10**, (2019).

572 21. Mi, H., Poudel, S., Muruganujan, A., Casagrande, J. T. & Thomas, P. D.
573 PANTHER version 10: expanded protein families and functions, and analysis
574 tools. *Nucleic Acids Res.* **44**, D336–D342 (2016).

575 22. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* **47**, D506–
576 D515 (2019).

577 23. Carlson, M. org.Hs.eg.db: Genome wide annotation for Human. R package
578 version 3.10.0.

579

Figures

Figure 1

Figure 2

A

CD4-positive, alpha-beta T cell

Cell Ontology ID	CL_0000624
Definition	A mature alpha-beta T cell that expresses an alpha-beta T cell receptor and the CD4 coreceptor.
Comment	
Broad Synonyms	
Exact Synonyms	<ul style="list-style-type: none"> CD4-positive, alpha-beta T lymphocyte CD4-positive, alpha-beta T-lymphocyte CD4-positive, alpha-beta T-cell
Related Synonyms	
References	Cell Ontology: CL_0000624

Related observations for the role of cell_biomarker

Showing 1 to 10 of 64 entries

[Export as Spreadsheet](#)

Filter this Table:

Publication Date	Observation Summary	PMID
Feb, 2019	In peripheral blood mononuclear cell, CD4-positive, alpha-beta T cell frequency was up for comparison females vs males in cohort adults (50-74) after exposure to Fluarix targeting Influenza A virus (A/California/7/2009(H1N1)) , Influenza A virus (A/Perth/16/2009(H3N2)) and/or Influenza B virus (B/Brisbane/60/2008) (details »)	30873150
Sep, 2018	In blood, CD4-positive, alpha-beta T cell & IFNG+, VZV-specific frequency was up for comparison pre-vaccination vs 72hrs post-vaccination in cohort adults (70-93) after exposure to Zostavax targeting Human alphaherpesvirus 3 (details »)	30247603

B

Observation

In blood, CD4-positive, alpha-beta T cell & IFNG+, VZV-specific frequency was **up** for comparison **pre-vaccination vs 72hrs post-vaccination** in cohort **adults (70-93)** after exposure to **Zostavax** targeting **Human alphaherpesvirus 3**

	Name	Class	Role	Description
	blood	CellSubset	tissue	tissue type
	CD4-positive, alpha-beta T cell	CellSubset	cell_biomarker	response component (cell subset)
	Human alphaherpesvirus 3	Pathogen	pathogen	target pathogen
	Zostavax	Vaccine	vaccine	exposure material (VO)

Study ([show details](#))

Evidence

Showing 1 to 33 of 33 entries

Filter this Table:

Type	Description	Details
------	-------------	---------

Figure 3

Table 1

Elements	Content Definition	Field value Example	Ontology	Data Type	Content Format
Response Component	The biological entity being observed: either a specific gene or cell subset	CKS1B	NCBI/HGNC for genes, Cell Ontology for cell types, PRO for proteins)	String	Controlled
Response Component Type	Type of response agent, e.g. gene, cell subset	gene		String	Fixed List
Tissue Type	The type of cells analyzed, e.g. whole blood, gated cells	whole blood (UBERON_0000178)	Blood + PRO/CL	String	Controlled
Exposure Process Type *	Category of immune exposure	Vaccination		String	Fixed List
Exposure Material *	Eg, the type of vaccine administered	VO_0001176	VO	String	Controlled
Disease Name *	The condition being observed	None	DO	String	Controlled
Disease Stage *	Stage of infection (e.g. acute, chronic, post, etc.)	None	OGMS	String	Controlled
Target Pathogen	The pathogenic organism (e.g. virus, bacterium, prion, fungus) being studied	Influenza A, Influenza B	NCBI Taxonomy ID	String	Controlled
Vaccine Year	Year for seasonal vaccines	2012		Numeric	Free text
Adjuvant	A substance added to vaccines to increase the body's immune response to the vaccine		VO	String	Controlled
Route	Eg oral, nasal spray, intradermal injection, etc.	Intramuscular, intradermal, transcutaneous	VO	String	Controlled
Scheduling	The number of times a substance is administered within a specific time period.	e.g. prime / boost scheme		String	Free text
Time Point		1		Numeric	
Time Point Units		day		String	Fixed List
Baseline Time	The starting point against which other events are compared	time of vaccination (first dose)		String	Free Text
Cohort	Features that describe study cohorts, if needed			String	Free Text
Subgroup	Features that split study cohorts, if needed. For example, a signature may have been discovered in a subset of the cohort with previous exposure history	MN antibody responders		String	Free Text
Age Group	broad age classification {infants (less than one year), children (less than 18 years), adults (less than 60 years), elderly}	adults		String	Fixed List
Age Min		18		Numeric	
Age Max		45		Numeric	
Age Units	{days, weeks, months, years}	years		String	Fixed List
Publication Reference	PubMed unique identifier of an article.	30843873		Numeric	Controlled
Publication Year	The year in which the study was published	2019		Numeric	
Publication Reference URL	Link to article in PubMed	https://www.ncbi.nlm.nih.gov/pubmed/30843873		String	URL
Comparison	The contrast used for deriving the signature	1d-0d		String	Free Text
Response Behavior	Observed change in the response agent under the comparison	Up		String	Free Text

Table 2

Signature Type	Vaccines	Target Pathogens	Publications	Signatures	Total Response Components	Response Components per Signature
Gene	52	38	62	480	13,821 genes	1 to 2,038 genes
Cell type	28	26	31	185	47 cell types	1 to 9 cell types
Joint	56	44	69	665		

Table 3

Column name	Ontology	Values
tissue_type	Cell Ontology	peripheral blood mononuclear cell
response_component	HGNC	STAT1, IRF9, SPI1, CD74, HLA-E, TNFSF13B
response_behavior		positive
subgroup		high responders
time_point		1
time_point_units		days
target_pathogen	NCBI Taxonomy	Influenza A virus (A/Brisbane/59/2007(H1N1)); Influenza A virus (A/Brisbane/10/2007(H3N2)); Influenza B virus (B/Florida/4/2006)
vaccine_year		2008
exposure_material	Vaccine Ontology	VO_0000045; VO_0000046 (Fluarix; Fluvirin)
comparison		correlated with titer response index (TRI)
cohort		adults (18-40)
publication_reference (PMID)		21357945